medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

#### A rare gain of function HCN4 gene mutation is responsible for 1 inappropriate sinus tachycardia in a Spanish family 2 3 Anabel Cámara-Checa,<sup>1,2\*</sup> Francesca Perin,<sup>3,4\*</sup> Marcos Rubio-Alarcón,<sup>1,2</sup> María 4 Dago,<sup>1,2</sup> Teresa Crespo-García,<sup>1,2</sup> Josu Rapún,<sup>1,2</sup> María Marín,<sup>2</sup> Jorge Cebrián,<sup>1,2</sup> 5 Francisco Bermúdez-Jiménez,<sup>3,4,5</sup>Lorenzo Monserrat,<sup>2,6</sup> Juan Tamargo,<sup>1</sup> Ricardo 6 Caballero,<sup>1,2#</sup> Juan Jiménez-Jáimez,<sup>3,4</sup> Eva Delpón.<sup>1,2#</sup> 7 8 9 <sup>1</sup>Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de 10 Madrid. Instituto de Investigación Gregorio Marañón. 28040-Madrid, Spain. 11 <sup>2</sup>CIBERCV. Instituto de Salud Carlos III. Spain. 12 <sup>3</sup>Department of Pediatric Cardiology. Virgen de las Nieves University Hospital. 18014-Granada, 13 Spain. <sup>4</sup>Instituto de Investigacion Biosanitaria de Granada IBS. 18014-Granada, Spain 14 15 <sup>5</sup>Centro Nacional de Investigaciones Cardiovasculares (CNIC). 28029-Madrid, Spain <sup>6</sup>Health in Code SL. 15008-A Coruña, Spain. 16 17 18 <sup>#</sup>Co-senior authors 19 \*Both authors contributed equally 20 21 Short title: p.V240M HCN4 and inappropriate sinus tachycardia 22 23 24 **Corresponding author:** 25 Ricardo Caballero Department of Pharmacology and Toxicology. 26 27 School of Medicine 28 Universidad Complutense de Madrid 29 Ramón y Cajal Square 30 28040-Madrid. SPAIN 31 rcaballero@ucm.es

32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a CC-BY 4.0 International lice Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

## 33 ABSTRACT

- Background. In a family with inappropriate sinus tachycardia (IST) we identified a novel
   mutation (p.V240M) of the hyperpolarization-activated cyclic nucleotide-gated type 4 (HCN4)
- 36 channel, which contributes to the pacemaker current (I<sub>f</sub>) in human sinoatrial node cells. Here we
- 37 clinically study the family and functionally analyze the p.V240M variant.
- Methods. Macroscopic (I<sub>HCN4</sub>) and single-channel currents were recorded using patch-clamp in
   cells expressing human native (WT) and/or p.V240M HCN4 channels.
- 40 Results. All p.V240M mutation carriers exhibited IST (mean heart rate 113[7] bpm, n=9), that in 41 adults, was accompanied by cardiomyopathy. I<sub>HCN4</sub> generated by p.V240M channels either alone 42 or in combination with WT was significantly greater than that generated by WT channels. The 43 variant, which lies in the N-terminal HCN domain, increased single-channel conductance and 44 opening frequency and probability of HCN4 channels. Conversely, it did not modify channel 45 sensitivity for cAMP and ivabradine or the level of expression at the membrane. Treatment with 46 ivabradine based on functional data reversed the IST and the cardiomyopathy of the carriers.
- 47 Conclusions. The p.V240M gain-of-function variant increases I<sub>f</sub> during diastole, which explains
  48 the IST of the carriers. The results demonstrate the importance of the unique HCN domain in
  49 HCN4 which stabilizes the channels in the closed state.
- 50
- 51 Funding. Ministerio de Ciencia e Innovación (PID2020-118694RB-I00); Comunidad Autónoma de
- 52 Madrid (P2022/BMD-7229), European Structural and Investment Funds); and Instituto de Salud
- 53 Carlos III (CIBERCV; CB16/11/00303).

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

## 54 INTRODUCTION

55 Inappropriate sinus tachycardia (IST) is a clinical syndrome with an estimated prevalence of around 1% (more frequent in young women) and a significant impact on the quality of life of the 56 57 affected individuals (Baruscotti et al., 2016; Olshansky and Sullivan, 2019). IST is defined by a 58 sinus heart rate (HR) inexplicably higher than 100 beats per min (bpm) at rest or higher than 90 59 bpm on average over 24 hours. The pathophysiology of IST is still not fully understood as the processes involved in pacemaking and its modulation are extremely complex (Baruscotti et al., 60 61 2016; Olshansky and Sullivan, 2019). Any participating mechanisms can affect the HR and result 62 in this syndrome, including an intrinsic increase in sinoatrial node automaticity (Baruscotti et al., 63 2016), excess sympathetic tone and reduced cardiovagal tone (Nwazue et al., 2014), and 64 circulating anti-beta-adrenergic receptor antibodies (Chiale et al., 2006), among others.

65 The hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family comprises 4 66 members (HCN1-4) and have the peculiarity that they are activated by hyperpolarization rather 67 than depolarization (Biel et al., 2009). These channels are expressed in the heart and in the central and peripheral nervous systems and exhibit a unique ion selectivity since they allow the 68 69 passage of a depolarizing mixed Na<sup>+</sup> and K<sup>+</sup> current (Biel et al., 2009). In the heart, the current is 70 known as pacemaker or funny current ( $I_f$ ) (because of its quite unusual biophysical profile) and 71 has a key role in controlling the rhythmic activity in sinoatrial node cells (Biel et al., 2009; 72 DiFrancesco, 2010; Hennis et al., 2022; Rivolta et al., 2020). Neuronal current is generally 73 designated as hyperpolarization-activated current or I<sub>h</sub> and contributes to controlling neuronal 74 excitability. HCN channels contain a cyclic nucleotide-binding domain (CNBD) in the carboxyl 75 terminus connected to the pore-forming S6 transmembrane segment via the C-linker (Lee and 76 MacKinnon, 2017). cAMP or cGMP binding to the CNBD induces a rightward shift of the voltage 77 dependence of HCN4 channel activation (DiFrancesco and Tortora, 1991; Wainger et al., 2001), 78 thus increasing the current. Furthermore, all HCN channel isoforms contain an N-terminal 79 domain (HCND) that, in HCN1 and HCN2 has been demonstrated to stabilize the closed pore in 80 the setting of a depolarized voltage sensor and that physically interacts with the CNBD and the 81 voltage-sensor domain (VSD) (Lee and MacKinnon, 2017; Porro et al., 2019). HCN family 82 members differ in their sensitivity to cAMP, opening kinetics, and preferential tissue distribution 83 (Biel et al., 2009). It is generally accepted that in all mammalian species studied so far, HCN4 was 84 found to be the main HCN channel isoform in the sinoatrial node although HCN1 and HCN2 85 isoforms are also present (Baruscotti et al., 2016, 2005; Shi et al., 1999). However, there are data

It is made available under a CC-BY 4.0 International licens Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

suggesting that HCN1 is the predominant isoform expressed in the human sinoatrial node (Li et

al., 2021, 2015).

88 In a large Spanish family with IST, we identified a novel heterozygous mutation (p.V240M) within 89 the HCND of HCN4 channels. Understanding the pathophysiology of IST is crucial to find a 90 treatment for this debilitating condition. For its part, the gating properties of HCN4 channels 91 and their role in cardiac pacemaking are currently not fully understood. Thus, we decided to clinically study all family members and functionally analyze the p.V240M HCN4 mutation 92 93 through biochemical and electrophysiological approaches even at the single-channel level. Our 94 results demonstrated that p.V240M is the first naturally occurring HCND gain-of-function 95 mutation causing an increased inward current flow during diastole accounting for the faster-96 than-normal heart rate of all carriers, that was reversed with treatment with ivabradine, a 97 selective HCN channel blocker (Baruscotti et al., 2005). Moreover, at the molecular level our 98 findings demonstrate the critical importance of the HCND in the gating o Our results strengthen 99 the importance of genetic and functional studies in families carrying mutations with uncertain 100 significance since they allow the implementation of a personalized treatment f HCN4 channels. 101 and help to the understanding of the mechanisms controlling human cardiac 102 electrophysiological properties.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity

perpetuity. It is made available under a CC-BY 4.0 International license . Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

#### 103 RESULTS

## 104 Clinical and genetic characteristics of the patients

105 The proband (III.3 in Figure 1A) is a female in her 30's (31-35), with a mean 24-h HR of 106[17] 106 bpm (Table 1 and Figure 1B). After a thorough evaluation, no reversible causes of sinus 107 tachycardia were found (i.e., hyperthyroidism, anemia, diabetes, orthostatic hypotension, 108 infections, and drug abuse), thus establishing the diagnosis of IST. The echocardiogram and 109 cardiac magnetic resonance (CMR) showed mild systolic dysfunction [left ventricular ejection fraction (LVEF)=43%], and no gadolinium enhancement. No signs of left ventricular 110 111 noncompaction or hypertrabeculation were found. Her resting HR and electrocardiographic 112 (ECG, in at least three different recordings) and cardiac structural parameters are described in 113 Table 2. Clinical evaluation of her relatives revealed that her father, two siblings, two sons, and 114 three nephews also fulfilled diagnostic criteria of IST, with a mean resting HR of 113[7] bpm 115 (Table 1 and Figure 1).





Figure 1. A family with inappropriate sinus tachycardia. (A) Pedigree of the IST proband's family. The arrow indicates
 the proband (III.3), circles and squares represent females and males, respectively. (B) Twelve-lead ECGs of II.1, III.3,
 and IV.9 family members (paper speed 25 mm/s).

120

Six more relatives were also clinically studied and none of them was diagnosed with IST (Table 1). No significant electrocardiographic or structural findings were detected in any of the IST patients (Table 2). However, all adults with IST (5 out of 9) had reduced LVEF without gadolinium enhancement, whereas children did not have cardiac dysfunction (Table 1 and Figure 1). As expected, the HR of children was higher than that of adults (mean 24-h HR: 115.2[5.3] *vs.* 102.7[2.1] bpm, P<0.05, n≥4). Patients IV.4 and IV.8 were diagnosed with fetal tachycardia with

It is made available under a CC-BY 4.0 International lice Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

- 127 HR at 160-170 bpm at birth (>98 percentile). The proband's aunt (II.3) had died after heart
- 128 transplant due to a congenital heart defect.
- These data suggested that in this family there was a genetic component responsible for the IST. Next-generation sequencing (Table Supplement File 1) of the proband identified the pathogenic (according to the guidelines for the interpretation of variants, Table 3 and Methods) heterozygous 15,73659894,C,T (NM\_005477.3:c.718G>A) variant in *HCN4* gene encoding p.V240M HCN4 (Figure 2A). The mutated residue is highly conserved among different species and lays in the HCND of the protein (Figure 2 B-D).
  - A В ANNAMIANAAAAAAMAAA R393 V240 HCND HCNa HCNb С CNBD 229-FSLRMFGSQKAVEREQERVKSAGF-252 Homo sapiens 229-FSLRMFGSQKAVEREQERVKSAGF-252 Pan troglodytes COOH 229-FSLRMFGSQKAVEREQERVKSAGF-252 Macaca mulata 229-FSLRMFGSQKAVEREQERVKSAGF-252 Mus musculus 229-FSLRMFGSQKAVEREQERVKSAGF-252 Rattus norvegicus 231-FSLRMFGSQKAVEREQERVKSAGF-254 Bos taurus Canis lupus dingo 224-FSLRMFGSQKAVEREQERVKSAGF-247 Equus caballus 229-FSLRMFGSQKAVEREQERVKSAGF-252 194-FSLRMFGSEKAVEREQERVKSAGF-217 Takifugu rubripes 190-FSLRMFGSEKAVEREQERVKSAGF-213 Danio rerio \*\*\*\* • \* \* \* D HCN1 **9**5 –QRQFTSMLQPGVNKFSLRMFGSQKAVEKEQERVKTAGF–132 137-QRQFGALLQPGVNKFSLRMFGSQKAVEREQERVKSAGA-174 HCN2 HCN3 46 -RRHLGTLLQPTVNKFSLRVFGSHKAVEIEQERVKSAGA-83 HCN4 215-QRQFGAMLQPGVNKFSLRMFGSQKAVEREQERVKSAGF-252 \* \*\*\* \*\*\*\*\* \*\*\* \*\* \*\*\*\*\* \*\*

135

Figure 2. The V240 residue is highly conserved and lays in the HCND of the protein. (A) DNA sequence chromatogram depicting the heterozygous *HCN4* variation (15,73659894,C,T; c.718G>A) in the proband. (B) Schematic diagram of human HCN4 channel highlighting some key domains and the approximate location of the p.V240M variant. (C and D) Sequence alignment of the region surrounding the V240 residue in HCN4 of several species (C) or in the four channels of the HCN family (D). The boxes in panels C and D highlight the conservation of this residue.

141

The p.V240M variant has been previously annotated with an allele frequency of 0.000003982 (https://gnomad.broadinstitute.org, accession date: 11/21/2022) since it was detected on a single allele in a south Asian subject. Cascade screening demonstrated the genotype-phenotype co-segregation of the *HCN4* variant (Figure 1A). All carriers except II.1, who refused any

It is made available under a CC-BY 4.0 International licer Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

treatment, were initially treated with ivabradine alone (7.5 mg BID for adults and 5 mg BID for the youngest carrier) with a significant response in terms of mean 24-h HR decrease (94[7] vs. 109[7.9], P<0.05) and improvement in symptoms and quality of life (Table 1). Three adult patients had their ivabradine dose reduced (5 mg BID) since they experienced mild weakness and dizziness, which are frequently associated with the use of this drug. Bisoprolol (5 mg BID) was added to them to achieve a better HR control (from 91[1.5] before to 84[5] after bisoprolol).

## 152 Macroscopic current analysis

To test whether the p.V240M HCN4 mutation underlies the IST in this family we functionally analyzed this variant. Figure 3A shows macroscopic HCN4 current (I<sub>HCN4</sub>) traces generated in three different CHO cells transfected with WT, p.V240M, and the combination of WT and p.V240M HCN4 channels (0.5:0.5 ratio). I<sub>HCN4</sub> comprises two components (inset in Figure 3A): the minor instantaneous (I<sub>INS</sub>) and the major slowly developing steady-state current (I<sub>SS</sub>), whose amplitude progressively increased at more negative potentials (Biel et al., 2009; Mistrík et al., 2006).



160

Figure 3. Macroscopic currents generated by WT and p.V240M HCN4 channels. (A and B) I<sub>HCN4</sub> traces (A) and density–voltage relationships (B) generated in CHO cells transiently expressing WT, p.V240M, and WT+p.V240M HCN4 channels by applying the protocol depicted at the top. The inset in A shows the minor instantaneous (I<sub>INS</sub>) and the major slowly developing steady-state HCN4 current (I<sub>SS</sub>) and the inset in B, shows the data at potentials positive to

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

-90 mV in an expanded scale. (C) Normalized tail current densities generated by WT, p.V240M, and WT+p.V240M
channels by applying 1-second pulses to −140 mV were plotted against the membrane potential of the test pulse.
Continuous lines represent the Boltzmann fit to the data. (D) Fully activated I<sub>HCN4</sub> density–voltage relationships
generated by WT, p.V240M, and WT+p.V240M channels. Continuous lines represent the linear regression to the data.
In B-D, each point represents the mean±SEM of ≥15 experiments/cells (biological replicates) from ≥3 dishes. In B,
\*P<0.05 vs. HCN4 WT. #P<0.05 vs. HCN4 WT and P<0.05 vs. p.V240M. Two-way ANOVA and Multiple t-test.</li>
Figure 3-source data 1 of panels B, C, and D.

172

I<sub>HCN4</sub> generated by p.V240M channels (measured at the end of the pulses) was significantly 173 174 greater than that generated by WT channels (Figure 3A and 3B) in a wide range of membrane 175 potentials that includes physiological membrane potentials (-1.2±0.2 vs. -8.6±2.6 pA/pF at -60 176 mV; P<0.05, n=19) (Table 4). Interestingly, densities of  $I_{HCN4}$  generated by the cotransfection of 177 WT and p.V240M channels were also significantly greater than those of WT channels (Figure 3A 178 and 3B and Table 4). Figure 3C shows that the p.V240M variant either alone or in combination 179 with WT channels, significantly and markedly shifted the midpoint (Vh) of the activation curve 180 to more depolarized membrane potentials as assessed by Boltzmann fits (Table 4).

Activation time constant ( $\tau_{act}$ ) at -160 mV averaged 509±40, 354±42, and 438±40 ms for I<sub>HCN4</sub> generated by WT, p.V240M, or WT+p.V240M HCN4 channels, respectively (Figure 4). Thus, the p.V240M mutation either alone or in combination with WT channels, significantly accelerated the activation of I<sub>HCN4</sub> (P=0.026, n≥17).



perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

186 Figure 4. p.V240M HCN4 modifies the time dependence of  $I_{HCN4}$  activation. (A) Mean time constant of activation ( $\tau_{act}$ ) 187 yielded by the fit of a monoexponential function to the activating phase of HCN4 current (I<sub>HCN4</sub>) traces elicited by pulses to -160 mV in cells expressing WT, p.V240M or WT+p.V240M channels. Each bar represents the mean±SEM of n 188 189 experiments and each dot represents one experiment. (B) I<sub>HCN4</sub> traces recorded by applying the protocol shown at the 190 top to measure deactivation kinetics consisting of two 3-s pulses from -40 to -120 mV that were applied at increasing 191 coupling intervals (1-6 s). For each coupling interval, we measured the instantaneous current ( $\Delta I_{INS}$ ) and the steady-192 state current (Iss) elicited at the beginning and at the end, respectively, of the second pulse to -120 mV. (C) Mean 193 Δl<sub>INS</sub>/lss measured at each coupling interval for I<sub>HCN4</sub> recorded in cells expressing WT, p.V240M or WT+p.V240M 194 channels. A monoexponential function was fitted to the data to obtain the time constant of deactivation (tdeact). Each 195 point was the mean±SEM of ≥7 experiments (biological replicates). In A and C, \*P<0.05 vs WT. Two-way ANOVA and 196 multiple t-test. An F-test was performed to determine the statistically significance of the differences between activation 197 time constants obtained in E.

198 Figure 4-source data 1 of panels A and C.

199

200 Channel deactivation properties were analyzed using a double pulse protocol (Schweizer et al.,

201 2010). Figure 4C shows that deactivation of p.V240M channels alone, but not in combination

with WT, was significantly slower than that of WT channels (P<0.05, n≥7) and, as a consequence,

the ratio of p.V240M channels that remained activated is greater for all the interpulse intervals

204 (Table 4).

205

## 206 Effects of cAMP on p.V240M HCN4 channels

207 Interestingly, effects produced by the p.V240M variant are quite similar to those produced by 208 cAMP (DiFrancesco and Tortora, 1991) and thus, we hypothesized that the mutation increases 209  $I_{HCN4}$  by augmenting HCN4 channel affinity for cAMP. Since HCN4 activation is not affected by 210 cAMP when channels are expressed in CHO cells (Peters et al., 2020), we tested our hypothesis 211 in HEK293 cells that were exposed to a saturating cAMP concentration (10  $\mu$ M) in the whole-cell 212 pipette solution.

It is made available under a CC-BY 4.0 International lic Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia



213

Figure 5. Effects of cAMP on the voltage dependence of  $I_{HCN4}$  activation. (A and B) Voltage dependence of  $I_{HCN4}$ generated by WT (A) and p.V240M (B) channels expressed in HEK293 cells in the presence or absence of 10  $\mu$ M cAMP. Tail current densities generated by applying 1-s pulses to -140 mV were normalized and plotted against the membrane potential of the test pulse. Continuous lines represent the Boltzmann fit to the data. Each point represents the mean±SEM of ≥6 experiments/cells (biological replicates) from ≥3 dishes.

219 Figure 5-source data 1 of panels A and B.

220

As expected, cAMP significantly shifted the activation curve of WT HCN4 channels toward depolarizing potentials (Figure 5A). In HEK293 cells the Vh of p.V240M HCN4 channel activation was also significantly more depolarized than that of WT channels (-111.3 $\pm$ 3.8 mV, n≥8, P<0.05). Importantly, voltage-dependent activation of p.V240M channels was significantly shifted in the presence of cAMP (-97.1 $\pm$ 5.2 mV, n≥6, P<0.05) (Figure 5B).

226

# 227 Effects of the p.V240M HCN4 mutation on the membrane expression

To analyze whether an increase of the expression of p.V240M HCN4 channels at the plasma membrane accounted for the  $I_{HCN4}$  increase, we conducted a cell surface biotinylation assay (Figure 6) measuring the levels of expression of total HCN4 protein (inputs) and membrane fraction (biotinylated) by Western blot (WB) (Figure 6A). Figure 6B shows the densitometry of the relative surface expression of WT and p.V240M HCN4 subunits and demonstrates that there were not significant differences in the expression of mutated and WT channels (P>0.05, n=5).

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia





234

Figure 6. Membrane expression of WT and p.V240M HCN4 channels. Representative WB images (A) and 235 236 densitometric analyses (B) of biotinylation assays showing the total (input) or surface (membrane) expression of HCN4 in cells expressing WT or p.V240M channels. The cytosolic protein ezrin was used as a negative control. In B, each 237

- 238 dot represents 1 experiment and each bar the mean±SEM of n experiments (biological replicates). Unpaired Student 239 t-test.
- 240 Figure 6-source data 1 of panel A.

241 Figure 6-source data 2 of panel B.

- 242
- 243

#### 244 Single-channel properties of p.V240M HCN4 channels

245 Figure 7 shows representative single-channel traces recorded in CHO cells at -90 mV in the

- 246 absence (control, top panels) or the presence (bottom panels) of ivabradine (5  $\mu$ M), a selective
- 247 If inhibitor (Baruscotti et al., 2005), using the cell-attached configuration.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia



248

**Figure 7.** Single-channel recordings generated by WT and p.V240M HCN4 channels.

250 Single channel recordings obtained by applying 3-s pulses from 0 to -90 mV in cells expressing or not (A) WT (B) or

251 p.V240M (C) HCN4 channels in the absence and presence (D-F) of ivabradine 5  $\mu$ M.

252

In all experiments we confirmed that ivabradine perfusion completely inhibited the unitary HCN4 current ( $i_{HCN4}$ ). Importantly, the p.V240M mutation did not modify the HCN4 channel sensitivity to ivabradine (Figure 8). No single-channel recordings were obtained in nontransfected cells since they do not express endogenous HCN4 channels (Figure 7A and 7D).

257



258

Figure 8. p.V240M does not modify HCN4 channel sensitivity to ivabradine. Concentration-response curves for
 ivabradine-induced inhibition of the I<sub>HCN4</sub> recorded at –140 mV in cells expressing WT or p.V240M HCN4 channels.
 Solid lines represent the fit of a Hill equation to the data; the nH was fixed to unity, and bottom and top values to 0 and

perpetuity. It is made available under a CC-BY 4.0 International license . Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

- 262 100%, respectively. Each point was the mean±SEM of at least 3 experiments/cells (biological replicates). Statistical
- 263 comparison between both curves was analyzed by an F-test (P=0.51).
- Figure 8-source data 1.
- 265
- 266 *i*<sub>HCN4</sub> generated by WT channels (Figure 7B) was characterized by spontaneous openings followed
- by periods of channel closure yielding mean  $f_0$  and  $P_0$  values of 5.2±1.1 Hz and 0.11±0.02 (n=5),
- respectively (Figure 9A and 9B and Table 4).



269

Figure 9. Gating properties of WT and p.V240M HCN4 channels. Mean  $f_0$  (**A**),  $P_0$  (**B**) and open time (**C**) for  $i_{HCN4}$ recorded in cells expressing WT or p.V240M HCN4 channels. (**D**)  $i_{HCN4}$  amplitude generated by WT and p.V240M channels after applying pulses to -90 mV. (**E**)  $i_{HCN4}$ -voltage relationships generated by WT and p.V240M channels. In **A-D** each dot represents 1 experiment/cell and each bar the mean±SEM of n experiments/cells (biological replicates) as indicated in the figure. In **E** each point represents the mean±SEM of ≥4 experiments/cells (biological replicates). \*P<0.05 vs. WT. Unpaired Student t-test. An F-test was performed to determine the statistically significance of the differences between conductance values.

- 277 **Figure 9**-source data 1 of panels A-E.
- 278

279 Conversely,  $i_{HCN4}$  generated by p.V240M channels was characterized by openings in bursts 280 (Figure 7C). Accordingly, both  $f_0$  and  $P_0$  significantly increased, while the mean open time 281 significantly decreased compared to those of WT channels (P<0.05, n≥5) (Figure 9A-9C and Table 282 4). Moreover,  $i_{HCN4}$  amplitude generated by p.V240M channels at -90 mV (Figure 9D) and at all 283 membrane potentials tested was significantly greater than that of WT channels (Figure 9E,

It is made available under a CC-BY 4.0 International lice Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

P<0.05, n=5). Figure 9E shows that single-channel conductance (γ) derived from the linear</li>
regression of the current-voltage relationships of p.V240M channels was double than that of WT
channels (Table 4). Importantly, γ here obtained for WT channels (16.3±2.7 pS) is in agreement
with that previously reported for HCN4 channels (Brandt et al., 2009; Michels et al., 2005).
Gating kinetics was characterized by means of dwell-time histograms (Methods). Both close and
open dwell-time histograms were fitted by monoexponential functions (Figure 10) yielding

290  $\tau_{CLOSED}$  and  $\tau_{OPEN}$  of 68.1 and 17.3 ms, respectively for WT channels. The mutation significantly

291 reduced both the  $\tau_{CLOSED}$  and the  $\tau_{OPEN}$  (P<0.05) (Table 4 and Figure 10).



292

Figure 10. p.V240M modifies single channel gating kinetics. (A-D) Closed- (A and C) and open (B and D) dwell-time histograms for currents recorded in cells expressing HCN4 WT (A and B) or HCN4 p.V240M (C and D) (bin width= 25 ms). Continuous lines represent the fit of a monoexponential function to the data, which yielded the indicated closed (T<sub>CLOSED</sub>) and open (T<sub>OPEN</sub>) time constants. Histograms were obtained by pooling data from 5 (WT) and 10 (p.V240M) experiments (biological replicates). \*P<0.05 vs WT (F-test).

298 Figure 10-source data 1 of panels A-D.

299

## 300 Mathematical model of human sinoatrial action potentials

Figure 11A shows human sinoatrial APs obtained when running the Fabbri-Fantini-Wilders-Severi mathematical model (Fabbri et al., 2017) considering the I<sub>f</sub> generated by WT HCN4 channels. AP characteristics are described in Table 5. Spontaneous firing frequency of the AP

304 averaged 73.8 bpm and it was almost doubled (146.3 bpm) when APs were modeled considering

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

the I<sub>f</sub> generated by p.V240M channels (Figure 11A). The acceleration of the pacemaker frequency is consequence of the huge increase in the I<sub>f</sub> density produced by the mutation (Figure 11B). Interestingly, I<sub>f</sub> currents generated when considering the heterozygous presence of p.V240M channels are also greater than those generated by WT channels and the firing frequency (108 bpm) is close to that of the carriers of the mutation.

## Mathematical model of the human sinoatrial action potentials



310

Figure 11. Mathematical model of human sinoatrial node cell action potential. (**A** and **B**). APs (**A**) and I<sub>f</sub> (**B**) obtained when running the Fabbri-Fantini-Wilders-Severi model under basal conditions (WT; left), or after introducing the experimentally measured I<sub>HCN4</sub> changes induced by p.V240M alone (center) or together with WT (right).

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

## 314 DISCUSSION

315 In this study we identified several members of a family diagnosed with IST carrying a novel gain-316 of-function HCN4 variant. The results of our functional analysis demonstrated that p.V240M 317 variant markedly increases the  $f_0$  and the  $P_0$  and depolarizes the voltage dependence of HCN4 318 channels activation. Thus, the mutation increases I<sub>HCN4</sub> by altering the gating without modifying 319 the channel sensitivity for cAMP and ivabradine or the membrane expression. All these effects 320 account for the huge increase of I<sub>HCN4</sub>, which, in turn, explains the IST of the affected family 321 members who were treated with ivabradine, which reversed IST and tachycardia-induced 322 cardiomyopathy.

323 The p.V240M mutation is, to the best of our knowledge, the second HCN4 gain-of-function 324 mutation described in the literature. The first one was the p.R524Q HCN4 variant, that increases 325 the channel affinity for cAMP and was described in an Italian family with symptomatic sinus 326 tachyarrhythmia (Baruscotti et al., 2017). Conversely, many loss-of-function heterozygous 327 mutations in the HCN4 gene have been associated with sinus bradycardia that can be 328 accompanied, or not, with atrial fibrillation, atrioventricular block, structural diseases such as 329 noncompaction cardiomyopathy, and even QT prolongation (Alonso-Fernández-Gatta et al., 330 2021; Cambon-Viala et al., 2021; Macri et al., 2014; Milanesi et al., 2006; Nof et al., 2007; Rivolta 331 et al., 2020; Schweizer et al., 2010; Ueda et al., 2004; Verkerk and Wilders, 2015). As mentioned, 332 there has been important controversy regarding the role of HCN4 isoforms in generating human 333  $I_{\rm f}$  and in pacemaking of sinoatrial node. There are reports demonstrating that the predominant 334 HCN isoform at both the protein and RNA levels is HCN1 (Li et al., 2021, 2015). However, only a 335 few data on the literature suggested the contribution of HCN1 variants to HR. One of them is a 336 case report (Yu et al., 2021) showing two rare HCN1 heterozygous variants identified in a young 337 patient with profound sinus bradycardia. The second report identifies a polymorphic HCN1 338 variant that was associated with HR variability and schizophrenia (Refisch et al., 2021). 339 Conversely, dysfunctional HCN1 channels seem to play an important role in different forms of 340 epilepsy and neuropathic pain (DiFrancesco et al., 2019; He et al., 2019). Our results add further 341 support to the contention that in humans, HCN4 channels critically determine If density in 342 sinoatrial cells, thus regulating HR.

The V240 residue is located in the N-terminus, and variants in this domain are less commonly described than in the pore and C-terminal regions of HCN4 channels. The HCND is formed by a stretch of 45 aminoacids directly preceding the S1 transmembrane segment that consists of three  $\alpha$ -helices (HCNa, HCNb, and HCNc) (Figure 2) (Lee and MacKinnon, 2017). The V240

It is made available under a CC-BY 4.0 International licen Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

residue is actually located in the HCNc α-helix. The HCND could act as a sliding crank that
converts the planar rotational movement of the CNBD into a rotational upward displacement of
the VSD mechanically coupling thus, the CNBD and the VSD (Porro et al., 2019; Wang et al.,
2020). HCND normally keeps the VSD in a position, which is unfavorable for channel opening
(Porro et al., 2019). To test the possible molecular mechanism responsible for the gain-offunction effects of p.V240M we have mutated *in silico* a human HCN4 model (PDB:6GYN, Figure
12).



354

355 Figure 12. Molecular modeling of WT and p.V240M HCN4 channels. (A) Ribbon representation of the cryo-EM 356 structure of human HCN4 (PDB:6GYN). Only two diagonal subunits are shown for clarity. The transmembrane 357 segments (TM) are gray, the HCND is orange, the C-linker is red, the CNBD is blue, and the distal C helix is green. (B) 358 Close view of superimposed WT and V240M models (colour coded as in A). Sticks representation shows amino acids 359 side-chains from WT (cyan) and V240M (purple). V240 and M240 are shown as spheres. (C) Interaction of HCND with 360 the VSD showing the hydrophobic interactions of F229 with I404 and M407 from TM S4 (VSD) and Y258 from the loop 361 connecting HCND to TM S1, and polar contacts of K228 and Y409 in WT (red dashed line) or K228 and N227 in V240M 362 (yellow dashed line). Spheres represent the van der Waals surface occupied by the side chains.

363

In HCN4 channels the HCND is anchored to the VSD by means of phenylalanine F229, whose aromatic side chain is inserted between transmembrane helices S1 and S4 in a hydrophobic pocket formed by I404 and M407 in S4, and Y258 in S1 (Figure 12B-C). Interestingly, the introduction of the methionine residue at this position remarkably reduced the energy in the most stable p.V240M conformation (-23.49 kcal/mol) compared to WT (-60.18 kcal/mol). Moreover, our molecular modeling demonstrates that the mutation introduces a slight torsion medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

of the aromatic group of F229 and prevents the H-bond between K228 in HCND and Y409 in S4
(Figure 12C). These effects might weaken the interaction between HCND and VSD. Thus, these
results suggest that p.V240M mutation limits the inhibitory action of the HCND on the VSD. The
latter could explain the marked positive displacement (≈20 mV) of the activation curve of
p.V240M channels. Indeed, our results are in accordance with those obtained by Porro et al
(Porro et al., 2019) who showed that disrupting the interaction between the HCND and the S4
TM of the VSD produced a depolarizing shift in the voltage dependence of activation.

377 The cAMP-induced movement of the C-linker produced by the binding of cAMP to the CNBD is 378 transmitted via the HCND to the VSD, lowering the energy barrier for channel opening (Porro et 379 al., 2019; Wang et al., 2020). The mutants that disrupt the contact between the CNBD and the 380 HCND eliminate the effect of cAMP on channel activation (Porro et al., 2019; Wang et al., 2020). 381 Results of the molecular modeling demonstrated that the interaction between CNBD and HCND 382 is not affected by the p.V240M mutation (Figure 12C). The latter would explain why p.V240M 383 channels are sensitive to cAMP. Interestingly, our results demonstrated that p.V240M mutation 384 markedly increases single HCN4 channel conductance, an effect that is beyond the positive shift 385 of the activation curve. We propose that somewhat the mutation introduces changes in the pore 386 region that controls the conductance of the channel, even when the channel selectivity is not 387 affected. In summary, and considering that there are very few reports describing single-channel 388 currents generated by HCN4 channels (Brandt et al., 2009; Michels et al., 2005), our results 389 contribute to the understanding of the role of HCND in the distinctive biophysical properties of 390 these channels.

The HCND is also necessary for the folding and trafficking of the channel to the plasma membrane (Porro et al., 2019; Wang et al., 2020). To the best of our knowledge, the only naturally occurring HCND mutation described so far is p.P257S which was identified in patients with early-onset atrial fibrillation (Macri et al., 2014). p.P257S channels present a trafficking defect being retained at the endoplasmic reticulum (Macri et al., 2014). Conversely, the p.V240M mutant is properly expressed in the membrane suggesting that p.V240M mutation does not affect the folding and trafficking of HCN4 subunits.

## 398 Clinical implications

399 IST is a relatively common clinical entity producing highly distressing symptoms. In most cases, 400 it is a sporadic non-familial-disease. Here we describe an autosomal-dominant form of IST with 401 a striking complete penetrance. The clinical manifestations of the carriers are noteworthy, as 402 they presented with systolic dysfunction. In fact, IST is barely associated with heart dysfunction medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentitiv

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

403 and tachycardia-induced cardiomyopathy (Olshansky and Sullivan, 2019; Sheldon et al., 2015a) 404 although some cases have been already reported (Romeo et al., 2011; Winum et al., 2009). Even 405 when HCN4 mutations have been related with noncompaction cardiomyopathy (Alonso-406 Fernández-Gatta et al., 2021), no signs of hypertrabeculation were found with CMR imaging or 407 echocardiography in this family. The fact that ivabradine reversed systolic ventricular 408 dysfunction suggests that the high HR and the duration of the arrhythmia (present from 409 childhood but being documented even before birth in 2 patients) could have been the major 410 contributors to cardiac dysfunction in our patients. Regarding treatment of IST, carriers were 411 treated with ivabradine, since previous reports demonstrated that it reduced HR and improved 412 quality of life in patients with IST (Cappato et al., 2012). Interestingly, the HR reduction in our 413 study with ivabradine alone was ≈14% which is similar to that obtained previously in patients 414 with IST of an unknown origin (Benezet-Mazuecos et al., 2013; Cappato et al., 2012). 415 Responsiveness of our patients to ivabradine can be explained considering that sensitivity of 416 p.V240M channels was identical to that of WT HCN4. These results strengthen the importance 417 of genetic and functional studies for the design of personalized therapies in patients with 418 inherited arrhythmogenic syndromes.

The degree of activation of I<sub>f</sub> at the end of an AP determines the steepness of phase 4 depolarization; hence, the frequency of AP firing (Verkerk and Wilders, 2015). Thus, it seems reasonable to assume that the gain-of-function p.V240M mutation is responsible for an increase in sinoatrial node automaticity and the IST of the affected subjects in this family.

## 423 Conclusions

424 Our results support the view that individuals carrying the p.V240M mutation present higher than 425 normal I<sub>HCN4</sub>. This variant increases I<sub>HCN4</sub> by an unprecedented mechanism that implies the 426 alteration of the gating without modifying the channel sensitivity for cAMP or the membrane 427 expression. Therefore, p.V240M is the first naturally occurring gain-of-function HCND variant 428 which explains the faster than normal HR and IST of the carriers. The clinical, genetic and 429 functional study of the variant led to the establishment of the personalized treatment with 430 ivabradine for all carriers, contribute to shed light in the understanding of the pathophysiology 431 of IST and help to the understanding the role of HCN4 channels in the pacemaker activity of 432 human sinoatrial cells.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

## 433 Methods

### 434 Study approval.

All patients signed an informed consent, and the study was approved by the Research Ethics Committee of Granada (ref: CEIM/CEI/3-19 [12/4/19]. The purpose, methods and ethical aspects of this specific study were specifically assessed in an ordinary meeting of the Committee. Moreover, the study conforms to the principles outlined in the Declaration of Helsinki. Genetic results of the participants were reported following the guidelines proposed by the Working Group on Reporting Genetic Results in Research Studies (Bookman et al., 2006).

## 441 Clinical study.

442 The proband and relatives of a Spanish family with several members diagnosed with IST and left 443 ventricular (LV) systolic dysfunction were evaluated at the "Hereditary cardiovascular disease 444 unit" in the Cardiology Department of the Hospital Universitario Virgen de las Nieves. Trained 445 personnel performed at least three electrocardiograms ECG at rest to the proband and to all the 446 family members that gave their written informed consent. Family members either diagnosed or 447 not with IST underwent a serial 24-hour ECG monitoring (at least two for patients diagnosed 448 with IST). CMR was performed only to adult family members with IST. Three months after 449 initiation of medical therapy with ivabradine (7.5 mg BID in adults, 5 mg BID in children) or 450 ivabradine (5 mg BID) plus bisoprolol (5 mg BID), the 24-h Holter monitoring and echocardiogram 451 were repeated for every patient, and the findings were compared with those obtained before 452 treatment. The size of chamber, quantifications, and severity partition cut-offs of LV dysfunction 453 were measured according to the current guidelines (Sheldon et al., 2015b). IST was defined as 454 fast sinus rates (>100 bpm at rest or >90 bpm on average over 24 h) not due to underlying 455 causes. Thus, prior to IST diagnosis, other causes such as hyperthyroidism, anemia, diabetes 456 mellitus, orthostatic hypotension, infections, and drug abuse, were ruled out. A full pedigree 457 was obtained collecting information such as cardiac events (sudden cardiac death, heart transplantation or device implantation), cases of IST, or systolic dysfunction of unknown etiology 458 459 and any kind of cardiomyopathy across 4 generations. Echocardiographic, ECG, and imaging 460 recordings were interpreted by experienced cardiologists, blinded to the genetic and clinical 461 data of the participants. QT values were corrected using the Bazzet's and Fredericia's formulas 462 in subjects with HR <100 and  $\geq$ 100 bpm, respectively.

463 Next-generation and Sanger sequencing.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

464 The genetic analysis of the proband was conducted by using a next-generation sequencing panel 465 including 197 genes (Table Supplement File 1) following procedures previously described (Caballero et al., 2017; Nieto-Marín et al., 2022). Genomic DNA was extracted using an 466 automated extraction and purification process by using the QIAsymphony SP® kit (Qiagen, Hilde, 467 468 Germany) according to the manufacturer's instructions. Library preparation was carried out 469 using SureSelect Reagent kit (Agilent, Santa Clara, CA, USA) for Illumina's paired-end multiplexed 470 sequencing method, following the manufacturer's instructions. The enrichment of the regions of interest was performed by means of a SureSelect (Agilent) probe kit that selectively captures 471 472 the coding zones and the flanking intronic areas of the selected genes. After the generation of 473 clusters, the DNA libraries were sequenced on the Illumina HiSeg 1500 platform. The analysis of 474 the sequencing data was performed using a proprietary bioinformatics pipeline to obtain a 475 report of variants noted along with their coverage and corresponding quality parameters. We 476 excluded variants located in introns (except those in suspected splicing sites) or intergenic 477 regions. We also removed synonymous variants and non-synonymous variants with occurrences 478 >1 in our local database. The list of variants identified were evaluated against database 479 information on previously described variants [Human Gene Mutation Database 480 (http://www.hgmd.cf.ac.uk/), Single Nucleotide Polymorphism (SNP) database 481 (http://www.ncbi.nlm.nih.gov/SNP/), NHLBI Exome GO Sequencing Project 482 (https://www.ncbi.nlm.nih.gov/clinvar/), (http://evs.gs.washington.edu/EVS), ClinVar or 483 Genome Aggregation database (http://gnomad.broadinstitute.org). Pathogenicity of the 484 identified variants was established according to the current recommendations of the American 485 College of Medical Genetics and Genomics and the Association for Molecular Pathology 486 (Richards et al., 2015). Variant pathogenicity was graded according to its presence in a previously 487 associated or candidate gene and the in silico predicted impact on the protein using widely used 488 software (PROVEAN, SIFT, Polyphen2, Mutation Taster, and Combined Annotation Dependent 489 Depletion Score), the degree of conservation of the affected residue measured by multiple 490 ortholog alignment using Alamut software (<u>http://www.interactive-biosoftware.com</u>).

A phenotype-genotype segregation study was conducted through cascade screening among
available relatives with Sanger genetic study (Caballero et al., 2017; Nieto-Marín et al., 2022).
PCR products were purified using illustra ExoProStar 1-Step (GE Healthcare Life Sciences,
Chicago, IL, USA) and the analysis was performed by direct sequencing (Health in Code, A
Coruña, Spain). The results were compared with the reference sequence from hg19 by means of
Chromas Lite Software (http://technelysium.com.au).

497

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

#### 498 Cell culture and transfection.

499 The study has been conducted in CHO and HEK-293 purchased from American Type Culture 500 Collection (ATCC, Manassas, VA, USA). They had been authenticated by the supplier as 501 appropriate. Mycoplasma tests were conducted routinely for both cell lines and showed no 502 mycoplasma contamination.

503 CHO cells were grown in Ham-F12 medium supplemented with 10% fetal bovine serum, 100 504 U/ml penicillin, and 100 μg/ml streptomycin (Caballero et al., 2010; Caballero et al., 2017; Pérez-505 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). HEK-506 293 cells were cultured in Dulbecco's modified Eagle's (DMEM) medium supplemented with 10% 507 fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin as previously described 508 (Caballero et al., 2010; Crespo-García et al., 2023). The cultures were passed every 2-5 days 509 using a brief trypsin treatment.

510 The p.V240M HCN4 mutation (NP 005468.1) was introduced by using the QuikChange Site-511 Directed Mutagenesis kit (Agilent, Santa Clara, CA, USA) and confirmed by direct DNA 512 sequencing (Secugen S.L., Madrid, Spain). The sequence of the oligonucleotides used to 513 5' introduce the p.V240M substitution the following: was sense 5' 514 GCAGCCAGAAAGCCaTGGAGCGCGAACAG 3'; antisense CTGTTCGCGCTCCAtGGCTTTCTGGCTGC 3'. The sequence of the oligonucleotide used for 515

516 sequencing was: 5' ACGGACACCTGCATGACTC 3'.

517 For macroscopic current recordings, subconfluent cultures were transiently transfected with 518 cDNA encoding WT or mutated HCN4 channels (1.6 μg) together with cDNA encoding the CD8 519 antigen (0.5 μg) by using X-tremeGENE™ HP (Roche Diagnostics, Rotkreuz, Switzerland) in CHO 520 cells or Lipofectamine 2000 (Thermofisher Scientific, Waltham, MA, USA) in HEK-293 cells, with manufacturer instructions followed (Caballero et al., 2010; Caballero et al., 2017; Pérez-521 522 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). In some experiments, WT and p.V240M HCN4 were cotransfected (WT+p.V240M) at a 0.5:0.5 ratio (0.8 523 524  $\mu g$  each). For single channel recordings, CHO cells were transfected with 0.5 instead of 1.6  $\mu g$  of 525 the cDNA encoding mutated or WT HCN4.

526 In all cases, at the point of 48 h after transfection, cells were incubated with polystyrene 527 microbeads precoated with anti-CD8 antibody (Dynabeads M450, Thermofisher Scientific). Most 528 of the cells that were beaded also exhibited channel expression. The day of recordings, cells 529 were removed from the dish by using a cell scraper or by trypsinization, respectively, and the 530 cell suspension was stored at room temperature and used within 12 h for electrophysiological 531 experiments.

22

medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentitiv

perpetuity. It is made available under a CC-BY 4.0 International license . Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

532 To minimize the influence of the expression variability, each construct was tested in a large

533 number of cells obtained from at least 3 different cell batches. Moreover, to avoid putative

534 interferences of culture conditions (passage number, cell density, etc), currents generated by

cells expressing WT, p.V240M and WT+p.V240M channels were always recorded in parallel.

## 536 **Recording techniques.**

## 537 Macroscopic current recordings.

538 A small aliquot of cell suspension was placed in a 0.5 ml chamber mounted on the stage of an 539 inverted microscope (Nikon TMS; Nikon Co., Tokio, Japan). After settling to the bottom of the 540 chamber, cells were perfused at  $\approx 1$  mL/min with external solution (see the composition below). 541 Macroscopic currents were recorded at room temperature (21-23°C) by means of the whole-542 cell patch-clamp technique using Axopatch-200B patch clamp amplifiers and pCLAMP software 543 (Molecular Devices, San José, CA, USA) (Caballero et al., 2010; Caballero et al., 2017; Pérez-544 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Nieto-Marín et al., 2022; Crespo-545 García et al., 2023) Recording pipettes were pulled from 1.0 mm o.d. borosilicate capillary tubes 546 (GD1, Narishige Co., Ltd, Tokio, Japan) using a programmable patch micropipette puller (Model P-2000 Brown-Flaming, Sutter Instruments Co., Novato, CA, USA) and were heat-polished with 547 548 a microforge (Model MF-83, Narishige). Micropipette resistance ranged 3-5 M $\Omega$  when filled with 549 the internal solution and immersed in the external solution. In all the experiments, series 550 resistance was compensated manually by using the series resistance compensation unit of the 551 Axopatch amplifier, and  $\geq$ 80% compensation was achieved. The remaining access resistance 552 after compensation and cell capacitance were  $1.7\pm0.4$  M $\Omega$  and  $11.9\pm0.7$  pF (n=65), respectively. 553 Therefore, under our experimental conditions no significant voltage errors (<5 mV) due to series 554 resistance were expected with the micropipettes used. Currents were filtered at half the 555 sampling frequency and stored on the hard disk of a computer for subsequent analysis. CHO 556 cells were perfused with an external solution containing (mM): NaCl 110, KCl 30, HEPES 5, MgCl<sub>2</sub> 557 0.5, CaCl<sub>2</sub> 1.8, and glucose 10; pH= 7.4 with NaOH. Recording pipettes were filled with an internal 558 solution containing (mM): K-aspartate 80, KCl 42,  $KH_2PO_4$  10, MgATP 5, phosphocreatine 3, 559 HEPES 5 and EGTA 5; pH 7.2 with KOH. The protocol to obtain current-voltage relationships 560 consisted of 2-s steps that were imposed in 10 mV increments from a holding potential of -40 561 mV to potentials ranging -160 and 0 mV. Current amplitude was measured at the end of the 562 pulse and normalized in each experiment to membrane capacitance to obtain current densities. 563 To determine putative effects on the ion selectivity of HCN4 channels, the reversal potential medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

564 (Erev) was measured at extracellular and intracellular K<sup>+</sup> concentrations of 30 and 142 mM, 565 respectively. To this end, 3-s pulses to -120 mV followed by 1-s pulse to membrane potentials 566 ranging -50 to +20 mV were applied. The  $E_{rev}$  was calculated in each experiment from the 567 intersection of the linear regression to the data with the abscissas axis. To analyze potential 568 effects on the time course of current activation, a monoexponential function was fitted to the activation phase of current traces elicited by pulses to -160 mV yielding  $\tau_{act}$  that defines the 569 570 process. To measure HCN4 deactivation kinetics, two 3-s pulses from -40 to -120 mV were 571 applied at increasing coupling intervals (1-6 s) (Mistrík et al., 2006; Schweizer et al., 2010). This 572 protocol allowed us to calculate, for each coupling interval, the ratio between  $\Delta I_{INS}$  and  $I_{SS}$  elicited 573 at the beginning and at the end, respectively, of the second pulse to -120 mV. The calculated 574 ratio was plotted as a function of the coupling interval and a monoexponential function was 575 fitted to the data to obtain the  $\tau_{deact}$ .

576 The protocol to analyze the voltage dependence of HCN4 channel activation consisted of 2-s 577 pulses from –40 mV to potentials ranging from –160 to 0 mV followed by 1-s pulses to –140 mV 578 to record the tail currents. The tail current amplitude was normalized to the maximum value 579 and plotted as a function of the membrane potential of the preceding pulse to construct the 580 activation curves. A Boltzmann function was fitted to the data to calculate the midpoint ( $V_h$ ) and 581 the slope (k) of the curves. In a subset of experiments, the consequences of the p.V240M variant 582 on the shift of the voltage-dependent activation produced by of 3',5'-cyclic Adenosine 583 monophosphate (cAMP) were analyzed in HEK-293 cells. It has been recently described that in 584 CHO but not in HEK-293 cells, HCN4 channel activation is constitutively shifted to more 585 depolarized membrane potentials and is no longer affected by cAMP (Peters et al., 2020). In 586 these experiments, HEK-293 cells cultured and transfected as described above, were perfused 587 with the same external solution than described for CHO cells (see above), while the internal 588 solution contained (mM): KCl 130, NaCl 10, MgATP 2, HEPES 5, MgCl<sub>2</sub> 0.5 and EGTA 1; pH 7.2 589 with KOH. cAMP (Merck, Rahway, NJ, USA) at a saturating concentration (10  $\mu$ M) was added to 590 the pipette solution.

591 The effects of different concentrations of ivabradine (0.1-3 µM) was determined in CHO cells 592 transfected with WT or p.V240M HCN4 channels by applying trains of activating/deactivating 593 steps to -140 and +5 mV from a holding potential of -35 mV (Bucchi et al., 2013). The  $I_{HCN4}$ 594 inhibition at -140 mV was used as an index of block (*f*; expressed as percentage of inhibition) to 595 construct the respective concentration-response curves and a Hill equation (f =596  $1/{1+(IC_{50}/[D])^{nH}})$  was fitted to the data to obtain the concentration needed to produce the 50% 597 of the maximum inhibition (IC<sub>50</sub>). In the fit,  $n_{H}$  was fixed to unity and bottom and top values were 598 constrained to 0 and 100%, respectively.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

599

#### 600 Single channel recordings.

601 Single channel currents were recorded in CHO cells at room temperature (21-23°C) using the 602 cell-attached patch-clamp configuration (Michels et al., 2005; Brandt et al., 2009; Caballero et 603 al., 2010; Crespo-García et al., 2023). Using this configuration, the intracellular environment is 604 completely preserved and channel activity can be measured in an intact cell. Cells were 605 suspended in bath solution containing (mM): KCl 130, NaCl 10, EGTA 5 and HEPES 10; pH 7.4 606 with KOH. This high-K<sup>+</sup> solution was used to achieve a resting membrane potential of zero. Patch 607 pipettes were pulled from 1.5 mm o.d. borosilicate capillary tubes (Harvard Apparatus Ltd, 608 Holliston, MA, USA), coated at the tip with Sylgard (Dow Corning, Midland, MI, USA), and fire-609 polished with a microforge (Mod. MF-830. Narishige). When filled with pipette solution 610 containing (in mM): KCl 70, NaCl 70, MgCl<sub>2</sub> 1, BaCl<sub>2</sub> 2 and HEPES 5; pH 7.4 with KOH, tip 611 resistances were between 5 and 10 M $\Omega$ . The micropipettes were gently lowered onto the cells 612 to get a gigaohm seal after applying suction. After seal formation, the cells were lifted from the 613 bottom of the perfusion bath and current recordings were started. Single channel currents were 614 recorded by applying repetitive 10-s pulses from a holding potential of -35 mV to -90 mV or to 615 potentials between -120 and +40 mV in 10 mV steps. Current data were sampled at 10 kHz and 616 filtered at 1 kHz. The apparent number of active channels in a patch was determined by visual 617 inspection of the current traces and patches with more than one channel were discarded. The 618 experimental conditions were optimized to reduce the number of active channels on each 619 recording: e.g., the amount of cDNA used for cell transfection was reduced by ≈70% and the tip 620 resistance of the pipettes was increased approximately threefold compared to whole-cell 621 recordings. Under these conditions, only 10% of cells with active channels had more than one 622 channel. All data analysis was performed by using pCLAMP software and opening events were 623 captured using the event detection tool of Clampfit 10 (Caballero et al., 2010; Crespo-García et 624 al., 2023). At the end of each experiment, the HCN channel inhibitor ivabradine (5  $\mu$ M) (Bucchi 625 et al., 2006) was added to the external solution to specifically abolish single channel currents 626 generated by HCN4 channels.

627 Amplitude of unitary currents was determined for each experiment by direct measurements of 628 fully resolved openings, which allowed the calculation of average values. The opening 629 probability ( $P_0$ ) was obtained for each experiment by dividing the time that the channel remains 630 in the open state by the total recording time and the opening frequency ( $f_0$ ) was calculated for 631 each experiment as the inverse of the closed time between events. The mean open time was

It is made available under a CC-BY 4.0 International licen Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

calculated for each experiment by dividing the time the channel remains in the open state by the events. To measure opening and closing kinetics, dwell-time histograms were constructed by plotting pooled dwell-time data as a function of the number of events per bin that were fitted by monoexponential functions to calculate  $\tau_{OPEN}$  and  $\tau_{CLOSED}$ . Current–voltage relationships were constructed by plotting the single channel current amplitude as a function of the membrane potential and conductance ( $\gamma$ ) was calculated from the slope of the fit of a linear function to the data recorded at potentials between –120 and –60 mV.

639

## 640 Biotinylation assay.

641 A biotinylation assay was conducted in CHO cells using procedures previously described (Crespo-642 García et al., 2023). At the point of 48 h after transfection of HCN4 WT or p.V240M, CHO cells 643 were washed twice with ice cold phosphate-buffer saline (PBS) and biotinylated for 15 min at 644 4°C using PBS containing 0.5 mg/mL of EZ Link Sulfo-NHS-SS-Biotin (ThermoFisher). Plates were 645 washed twice with PBS-200 mM glycine (to quench unlinked biotin) and again with PBS. Cells 646 were collected in RIPA buffer containing 50 mM Tris·HCl (pH=7.5), 150 mM NaCl, 1% Nonidet P-647 40, 0.1% SDS, 0.5% sodium deoxycholate, and 1 mM phenylmethylsulfonyl fluoride (PMSF) and 648 protease inhibitor cocktail (Merck) for protein extraction. Subsequently, the extract (1 mg) was 649 incubated with Streptavidin Sepharose (50 μl, GE Healthcare) overnight at 4°C. To separate 650 biotinylated fraction, samples were centrifugated at 3000 rpm for 2 min at 4°C. The fraction of 651 biotinylated proteins was washed by several centrifugations. Thereafter, HCN4 and ezrin 652 proteins were detected by Western blot following previously described procedures (Pérez-653 Hernández et al., 2018; Nieto-Marín et al., 2022; Crespo-García et al., 2023). Nuclei and cell 654 debris were removed by centrifugation at 14.000 rpm for 20 min at 4°C. The total protein 655 amount of the extracts was calculated with the bicinchoninic acid method (Pierce™ BCA Protein 656 Assay Kit, ThermoFisher). Samples were run on 4-15% Mini-PROTEAN TGX<sup>™</sup> stain-free gels (Bio-657 Rad, Hércules, CA, USA USA) and, afterwards, protein was transferred to nitrocellulose 658 membranes. Nonspecific binding sites were blocked with 5% non-fat dried milk in PBS with 659 Tween-20 (0.05%) for 1 hour at room temperature. Membranes were then incubated with rabbit 660 polyclonal anti-HCN4 (1:1000; 55224-1-AP, Proteintech, Rosemont, IL, USA) and mouse 661 monoclonal anti-ezrin (1:400; ab4069, Abcam, Cambridge, UK) primary antibodies overnight at 662 4°C. All the antibodies had been validated by the manufacturers. After the incubation with the 663 primary antibodies, samples were incubated for 1 hour with peroxidase-conjugated goat anti-664 rabbit (111-035-144) or goat anti-mouse (115-035-003) secondary antibody (1:10000; Jackson

It is made available under a CC-BY 4.0 International licent Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

Immunoresearch, West Grove, PA, USA). Membranes were washed three times with PBS-Tween after adding primary and secondary antibodies. Protein expression was detected by chemiluminescence (SuperSignal<sup>™</sup> West Femto Maximum Sensitivity Substrate, ThermoFisher) and visualized using the Chemidoc MP System and Image Lab 5.2.1. software (Bio-Rad). Expression of the proteins in the biotinylated (membrane) fraction was normalized to the input expression.

671

## 672 Mathematical modeling of human sinoatrial node action potential.

673 We employed the Fabbri-Fantini-Wilders-Severi model of human sinus node cells (Fabbri et al., 674 2017). The model is based on experimental recordings and numerical reconstructions of the I<sub>f</sub> 675 measured in human sinoatrial node cells (Verkerk et al., 2007a, 2007b) and fairly reproduces the 676 changes in heart rate induced by mutations or drugs affecting the I<sub>f</sub> (Fabbri et al., 2017). We 677 downloaded the model files available at the CellML model repository (http://models.cellml.org/cellml), as part of the International Union of Physiological Sciences 678 679 Physiome Project (Yu et al., 2011). To perform the simulations we used OpenCell software 680 package that allows reading, modifying, solving, and plotting CellML models (http://cellml-681 opencell.hg.sourceforge.net:8000/hgroot/cellml-opencell/cellml-opencell). Initially, the model was run (for 100 s) keeping all parameters at their default values and under these conditions, 682 683 the model was stable and reproduced the results obtained in the original description of the 684 model (Fabbri et al., 2017). The results obtained with these "basal" conditions were considered 685 to correspond to WT HCN4. Thereafter, the experimentally measured changes produced by 686 p.V240M HCN4 or WT + p.V240M HCN4 on the conductance, kinetics and voltage dependence 687 of activation of the macroscopic I<sub>f</sub> were incorporated into the model equations corresponding 688 to the If. The modified versions of the model were also run for 100 s. In all cases, we plotted 689 action potential and I<sub>f</sub> traces yielded at the end of the simulation runs and several parameters 690 were measured including cycle length, beating frequency, diastolic depolarization rate, mean 691 diastolic potential, action potential amplitude, overshoot, and action potential duration 692 measured at 20, 50, and 90% of repolarization.

## 693 Molecular modeling.

To estimate the conformational changes produced by the p.V240M HCN4 mutation a molecular modeling using the crystallized structure of human HCN4 (PDB: 6GYN) was performed. Model refinement, in silico mutagenesis, and energy calculation were done with FoldX Suite (version medRxiv preprint doi: https://doi.org/10.1101/2023.01.20.23284606; this version posted January 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

697 4.0, https://www.foldxsuite.crg.eu). For model refinement and minimizing the energy of the 698 structure, the RepairPDB protocol was used. The Val-to-Met substitution at position 240 of each 699 monomer of the optimized PDB was performed and the protocol to calculate free energies was 700 run ten times. Default parameters of the software were used except temperature, pH, ionic 701 strength and VdW design that were set at 298K, 7, 5 and 0, respectively. When the model 702 running was completed, the software provided different conformations with different energies 703 and the conformation of the mutated form with the lowest energy was chosen. The optimized 704 conformations of WT and p.V240M HCN4 were compared on PyMOL (Molecular Graphics 705 System, Version 2.0 Schrödinger, LLC; https://www.pymol.org/2/) and putative changes in the 706 aminoacid positions and interactions (Hydrophobic, electrostatic and H-Bonds) with 707 surrounding residues induced by the presence of the mutation were identified (Caballero et al, 708 2010).

709

## 710 Statistical Analyses

711 Clinical and experimental results are expressed as mean[SD] and mean±SEM, respectively. 712 Small-sized samples were first analyzed to determine the distribution of the variables 713 (Normality) using the Shapiro–Wilk and Kilmogorov-Smirnov tests. When these tests 714 demonstrated a normal distribution, parametric tests were used. Paired or unpaired t test, 715 multiple t test, one-way ANOVA followed by Tukey's test, or two-way ANOVA were used to 716 assess statistical significance where appropriate. When a statistically significant difference was 717 determined by these tests, a Pearson correlation was performed to confirm that the observed 718 differences were not due to random sampling. To make comparisons between fits of pooled or 719 of concentration-dependent data, an F-test was used. Variance was comparable between 720 groups throughout the manuscript. A value of P<0.05 was considered significant. Statistical tests 721 were conducted using GraphPad Prism 8 (https://www.graphpad.com/scientific-722 software/prism/) or Microsoft Excel. For the different groups of experiments sample size was 723 chosen empirically according to previous experience in the calculation of experimental 724 variability. No statistical method was used to predetermine sample size. The cellular 725 experiments were not blinded due to the nature of the experimental design and platforms but 726 all the data were analysed in an identical manner for all conditions to eliminate possible operator 727 bias.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

#### 728 Data availability

- 729 All data generated or analyzed during this study are included in the manuscript and supporting
- 730 files. CMR and acute and Holter ECGs recordings will be not available since they are incorporated
- 731 into the confidential medical record of each participant.
- 732
- 733 **Disclosures**
- 734 The authors declare no conflict of interest

perpetuity. It is made available under a CC-BY 4.0 International license . Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

## 735 **REFERENCES**

736 Alonso-Fernández-Gatta M, Gallego-Delgado M, Caballero R, Villacorta E, Díaz-Peláez E, García-737 BerrocaL B, Crespo-García T, Plata-Izquierdo B, Marcos-Vadillo E, García-Cuenllas L, 738 Barreiro-Pérez M, Isidoro-García M, Tamargo-Menéndez J, Delpón E, Sánchez PL. 2021. A 739 rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and 740 hypertrabeculation/left ventricular noncompaction phenotype. Rev Espanola Cardiol Engl 741 Ed 74:781-789. doi:10.1016/j.rec.2020.06.019 742 Baruscotti M, Bianco E, Bucchi A, DiFrancesco D. 2016. Current understanding of the 743 pathophysiological mechanisms responsible for inappropriate sinus tachycardia: role of 744 the If "funny" current. J Interv Card Electrophysiol Int J Arrhythm Pacing 46:19–28. 745 doi:10.1007/s10840-015-0097-y 746 Baruscotti M, Bucchi A, Difrancesco D. 2005. Physiology and pharmacology of the cardiac 747 pacemaker ("funny") current. Pharmacol Ther 107:59-79. 748 doi:10.1016/j.pharmthera.2005.01.005 749 Baruscotti M, Bucchi A, Milanesi R, Paina M, Barbuti A, Gnecchi-Ruscone T, Bianco E, Vitali-750 Serdoz L, Cappato R, DiFrancesco D. 2017. A gain-of-function mutation in the cardiac 751 pacemaker HCN4 channel increasing cAMP sensitivity is associated with familial 752 Inappropriate Sinus Tachycardia. Eur Heart J 38:280–288. doi:10.1093/eurheartj/ehv582 753 Benezet-Mazuecos J, Rubio JM, Farré J, Quiñones MÁ, Sanchez-Borque P, Macía E. 2013. Long-754 term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate 755 efficacy or inappropriate patients. Pacing Clin Electrophysiol PACE 36:830-836. 756 doi:10.1111/pace.12118 757 Biel M, Wahl-Schott C, Michalakis S, Zong X. 2009. Hyperpolarization-activated cation 758 channels: from genes to function. Physiol Rev 89:847-885. 759 doi:10.1152/physrev.00029.2008 Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, Koski G, Motulsky A, 760 761 Wilfond B, Manolio TA, Fabsitz RR, Luepker RV; NHLBI Working Group. 2006. Reporting 762 genetic results in research studies: summary and recommendations of an NHLBI working 763 group. Am J Med Genet A. 140:1033-1040. doi: 0.1002/ajmg.a.31195. 764 Brandt MC, Endres-Becker J, Zagidullin N, Motloch LJ, Er F, Rottlaender D, Michels G, Herzig S, 765 Hoppe UC. 2009. Effects of KCNE2 on HCN isoforms: distinct modulation of membrane 766 expression and single channel properties. Am J Physiol Heart Circ Physiol 297:H355-363. 767 doi:10.1152/ajpheart.00154.2009 768 Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. 2006. Properties of ivabradine-769 induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572:335–346. 770 doi:10.1113/jphysiol.2005.100776 771 Bucchi A, Baruscotti M, Nardini M, Barbuti A, Micheloni S, Bolognesi M, DiFrancesco D. 2013. 772 Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS One 773 8:e53132. doi:10.1371/journal.pone.0053132 774 Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L, 775 Duarte J, López-Izquierdo A, Moraleda I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón 776 E. 2010. Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing 777 the polyamine-induced rectification. Proc Natl Acad Sci U S A 107:15631–15636. 778 doi:10.1073/pnas.1004021107 779 Caballero R, Utrilla RG, Amorós I, Matamoros M, Pérez-Hernández M, Tinaquero D, Alfayate S, 780 Nieto-Marín P, Guerrero-Serna G, Liu Q-H, Ramos-Mondragón R, Ponce-Balbuena D, 781 Herron T, Campbell KF, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Delpón E, 782 Tamargo J. 2017. Tbx20 controls the expression of the KCNH2 gene and of hERG channels. 783 Proc Natl Acad Sci U S A 114:E416–E425. doi:10.1073/pnas.1612383114

784	Cambon-Viala M, Gerard H, Nguyen K, Richard P, Ader F, Pruny J-F, Donal E, Eicher J-C, Huttin								
785	O, Selton-Suty C, Raud-Raynier P, Jondeau G, Mansencal N, Sawka C, Casalta A-C, Michel								
786	N, Donghi V, Martel H, Faivre L, Charron P, Habib G. 2021. Phenotype/Genotype								
787	Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are								
788	Associated With Preserved Left Ventricular Systolic Function and Biventricular								
789	Noncompaction: Phenotype/Genotype of Noncompaction. J Card Fail 27:677–681.								
790	doi:10.1016/j.cardfail.2021.01.007								
791	Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, Pittalis M, De								
792	Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di Francesco D, Lupo PP. 2012. Clinical								
793	efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective,								
794	randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol								
795	<b>60</b> :1323–1329. doi:10.1016/j.jacc.2012.06.031								
796	Chiale PA, Garro HA, Schmidberg J, Sánchez RA, Acunzo RS, Lago M, Levy G, Levin M. 2006.								
797	Inappropriate sinus tachycardia may be related to an immunologic disorder involving								
798	cardiac beta andrenergic receptors. <i>Heart Rhythm</i> <b>3</b> :1182–1186.								
799	doi:10.1016/j.hrthm.2006.06.011								
800	Crespo-García T, Rubio-Alarcón M, Cámara-Checa A, Dago M, Rapún J, Nieto-Marín P, Marín M,								
801	Cebrián J, Tamargo J, Delpón E, Caballero R. 2023. A Cantú syndrome mutation								
802	produces dual effects on KATP channels by disrupting ankyrin B regulation. J Gen								
803	Physiol 155:e202112995. doi:10.1085/jgp.202112995								
804	DiFrancesco D. 2010. The role of the funny current in pacemaker activity. <i>Circ Res</i> <b>106</b> :434–								
805	446. doi:10.1161/CIRCRESAHA.109.208041								
806	DiFrancesco D, Tortora P. 1991. Direct activation of cardiac pacemaker channels by								
807	intracellular cyclic AMP. <i>Nature</i> <b>351</b> :145–147. doi:10.1038/351145a0								
808	DiFrancesco JC, Castellotti B, Milanesi R, Ragona F, Freri E, Canafoglia L, Franceschetti S,								
809	Ferrarese C, Magri S, Taroni F, Costa C, Labate A, Gambardella A, Solazzi R, Binda A,								
810	Rivolta I, Di Gennaro G, Casciato S, D'Incerti L, Barbuti A, DiFrancesco D, Granata T,								
811	Gellera C. 2019. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a								
812	large cohort of patients and review of the literature. <i>Epilepsy Res</i> <b>153</b> :49–58.								
813	doi:10.1016/j.eplepsyres.2019.04.004								
814	Duhme N, Schweizer PA, Thomas D, Becker R, Schröter J, Barends TRM, Schlichting I, Draguhn								
815	A, Bruehl C, Katus HA, Koenen M. 2013. Altered HCN4 channel C-linker interaction is								
816	associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart								
817	J <b>34</b> :2768–2775. doi:10.1093/eurheartj/ehs391								
818	Fabbri A, Fantini M, Wilders R, Severi S. 2017. Computational analysis of the human sinus node								
819	action potential: model development and effects of mutations. <i>J Physiol</i> <b>595</b> :2365–2396.								
820	doi:10.1113/JP273259								
821	He J-T, Li X-Y, Zhao X, Liu X. 2019. Hyperpolarization-activated and cyclic nucleotide-gated								
822	channel proteins as emerging new targets in neuropathic pain. <i>Rev Neurosci</i> <b>30</b> :639–649.								
823	doi:10.1515/revneuro-2018-0094								
824	Hennis K, Biel M, Fenske S, Wahl-Schott C. 2022. Paradigm shift: new concepts for HCN4								
825	function in cardiac pacemaking. <i>Pflugers Arch</i> <b>474</b> :649–663. doi:10.1007/s00424-022-								
826	02698-4								
827	Lee C-H, MacKinnon R. 2017. Structures of the Human HCN1 Hyperpolarization-Activated								
828	Channel. <i>Cell</i> <b>168</b> :111-120.e11. doi:10.1016/j.cell.2016.12.023								
829	Li N, Artiga E, Kalyanasundaram A, Hansen BJ, Webb A, Pietrzak M, Biesiadecki B, Whitson B,								
830	Mokadam NA, Janssen PML, Hummel JD, Mohler PJ, Dobrzynski H, Fedorov VV. 2021.								
831	Altered microRNA and mRNA profiles during heart failure in the human sinoatrial node.								
832	<i>Sci Kep</i> <b>11</b> :19328. doi:10.1038/s41598-021-98580-x								
833	LI N, Csepe I A, Hansen BJ, Dobrzynski H, Higgins RSD, Kilic A, Mohler PJ, Janssen PML, Rosen								
834	INIK, BIESIADECKI BJ, FEDOROV VV. 2015. MOLECULAR MAPPING OF SINOATRIAL NODE HCN Channel								

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

835	Expression in the Human Heart. <i>Circ Arrhythm Electrophysiol</i> <b>8</b> :1219–1227.
027	dol:10.1161/CIRCEP.115.003070
837	Miler DL Lurette KL Deniemin EL Elliner DT 2014 A neuel trefficking defective LCN4
000	which DJ, Lunella KL, Benjamin EJ, Ellinor PT. 2014. A novel tranicking-defective HCN4
839	mutation is associated with early-onset atrial libriliation. <i>Heart Rhythm</i> 11:1055–1062.
840	dol:10.1016/J.nrtnm.2014.03.002
841	Michels G, Er F, Khan I, Sudkamp M, Herzig S, Hoppe UC. 2005. Single-channel properties
842	support a potential contribution of hyperpolarization-activated cyclic nucleotide-gated
843	channels and if to cardiac arrhythmias. <i>Circulation</i> 111:399–404.
844	doi:10.1161/01.CIR.0000153799.65783.3A
845	Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. 2006. Familiai sinus bradycardia
846 047	associated with a mutation in the cardiac pacemaker channel. <i>IN Engl J Med</i> <b>354</b> :151–157.
047 010	UUI.10.1050/NEJIVI04052475 Mistrik B. Bfaifar A. Bial M. 2006. The ophansoment of HCN shapped instantaneous surrent
040 040	facilitated by clow deactivation is regulated by intracellular chloride concentration
049 050	Definitation by Slow deactivation is regulated by initiatential chloride concentration.
85U 851	PJIUgers Alcri 452./18-727. doi:10.1007/S00424-006-0095-0
051	Chara A, Dubio Alaraán M, Dago M, Alfaveto S, Filgueiros Dama D, Deinado D, Lánaz
052	Checa A, Rubio-Aldi Coll M, Dago M, Allayate S, Fliguellas-Rahla D, Pelhauo R, Lopez-
000 001	Sendon JL, Jame J, Tamargo J, Bernal JA, Caballero K, Delpon E, MACA Consortium
054 055	diagnosod with Brugada or Long OT Syndroma, Cardiovass Pas <b>119</b> :1046, 1060
055 055	dai:10.1002/our/ousb045
850	Nof E Juria D. Brass D. Marek D. Jabat H. Beznik-Wolf H. Bras E. Dascal N. Eldar M. Glikson M.
0J7 050	2007 Point mutation in the HCNA cardiac ion channel nore affecting synthesis trafficking
850 850	and functional expression is associated with familial asymptomatic sinus bradycardia
860	Circulation <b>116</b> :463–470 doi:10.1161/CIRCULATIONAHA.107.706887
861	Nwazue VC Paraniane SV Black BK Biaggioni   Diedrich & Dupont WD Robertson D Bai SR
862	2014 Postural tachycardia syndrome and inannronriate sinus tachycardia: role of
863	autonomic modulation and sinus node automaticity. <i>J Am Heart Assoc</i> <b>3</b> :e000700
864	doi:10 1161/JAHA 113 000700
865	Olshansky B. Sullivan RM, 2019, Inappropriate sinus tachycardia, <i>EP Eur</i> <b>21</b> :194–207.
866	doi:10.1093/europace/euv128
867	Pérez-Hernández M. Matamoros M. Alfavate S. Nieto-Marín P. Utrilla RG. Tinaquero D. de
868	Andrés R. Crespo T. Ponce-Balbuena D. Willis BC. Jiménez-Vazquez EN. Guerrero-Serna G.
869	da Rocha AM. Campbell K. Herron TJ. Díez-Guerra FJ. Tamargo J. Jalife J. Caballero R.
870	Delpón E. 2018. Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac
871	Kir2.1/2.2 channels. JCI Insight <b>3</b> . doi:10.1172/jci.insight.96291
872	Peters CH. Myers ME. Juchno J. Haimbaugh C. Bichraoui H. Du Y. Bankston JR. Walker LA.
873	Proenza C. 2020. Isoform-specific regulation of HCN4 channels by a family of endoplasmic
874	reticulum proteins. <i>Proc Natl Acad Sci U S A</i> <b>117</b> :18079–18090.
875	doi:10.1073/pnas.2006238117
876	Porro A, Saponaro A, Gasparri F, Bauer D, Gross C, Pisoni M, Abbandonato G, Hamacher K,
877	Santoro B, Thiel G, Moroni A. 2019. The HCN domain couples voltage gating and cAMP
878	response in hyperpolarization-activated cyclic nucleotide-gated channels. <i>eLife</i> 8:e49672.
879	doi:10.7554/eLife.49672
880	Refisch A, Chung H-Y, Komatsuzaki S, Schumann A, Mühleisen TW, Nöthen MM, Hübner CA,
881	Bär K-J. 2021. A common variation in HCN1 is associated with heart rate variability in
882	schizophrenia. Schizophr Res 229:73–79. doi:10.1016/j.schres.2020.11.017
883	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector
884	E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. 2015.
885	Standards and guidelines for the interpretation of sequence variants: a joint consensus
886	recommendation of the American College of Medical Genetics and Genomics and the

887	Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet 17:405–424.
888	doi:10.1038/gim.2015.30
889	Rivolta I, Binda A, Masi A, DiFrancesco JC. 2020. Cardiac and neuronal HCN channelopathies.
890	<i>Pflugers Arch</i> <b>472</b> :931–951. doi:10.1007/s00424-020-02384-3
891	Romeo E, Grimaldi N, Sarubbi B, D'Alto M, Santarpia G, Scognamiglio G, Russo MG, Calabrò R.
892	2011. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia:
893	efficacy of ivabradine. <i>Pediatr Cardiol</i> <b>32</b> :842–845. doi:10.1007/s00246-011-9964-1
894	Schweizer PA, Duhme N, Thomas D, Becker R, Zehelein J, Draguhn A, Bruehl C, Katus HA,
895	Koenen M. 2010. cAMP sensitivity of HCN pacemaker channels determines basal heart
896	rate but is not critical for autonomic rate control. <i>Circ Arrhythm Electrophysiol</i> <b>3</b> :542–552.
897	doi:10.1161/CIRCEP.110.949768
898	Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. 2005. The FoldX web server: an
899	online force field. Nucleic Acids Res 33:W382-388. doi:10.1093/nar/gki387
900	Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo
901	CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,
902	Moak JP, Sandhu RK, Kanjwal K. 2015a. 2015 heart rhythm society expert consensus
903	statement on the diagnosis and treatment of postural tachycardia syndrome,
904	inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i> <b>12</b> :e41-63.
905	doi:10.1016/j.hrthm.2015.03.029
906	Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo
907	CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,
908	Moak JP, Sandhu RK, Kanjwal K. 2015b. 2015 heart rhythm society expert consensus
909	statement on the diagnosis and treatment of postural tachycardia syndrome,
910	inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i> <b>12</b> :e41-63.
911	doi:10.1016/j.hrthm.2015.03.029
912	Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, Robinson RB, Dixon JE, McKinnon D, Cohen
913	IS. 1999. Distribution and prevalence of hyperpolarization-activated cation channel (HCN)
914	mRNA expression in cardiac tissues. <i>Circ Res</i> 85:e1-6. doi:10.1161/01.res.85.1.e1
915	Ueda K, Nakamura K, Hayashi T, Inagaki N, Takahashi M, Arimura T, Morita H, Higashiuesato Y,
916	Hirano Y, Yasunami M, Takishita S, Yamashina A, Ohe T, Sunamori M, Hiraoka M, Kimura
917	A. 2004. Functional characterization of a trafficking-defective HCN4 mutation, D553N,
918	associated with cardiac arrhythmia. J Biol Chem 279:27194–27198.
919	doi:10.1074/jbc.M311953200

- Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia
- 921 Verkerk AO, van Borren MMGJ, Peters RJG, Broekhuis E, Lam KY, Coronel R, de Bakker JMT, 922 Tan HL, Wilders R. 2007. Single cells isolated from human sinoatrial node: action 923 potentials and numerical reconstruction of pacemaker current. Annu Int Conf IEEE Eng 924 Med Biol Soc 2007:904-907. doi:10.1109/IEMBS.2007.4352437 925 Verkerk AO, Wilders R. 2015. Pacemaker activity of the human sinoatrial node: an update on
- 926 the effects of mutations in HCN4 on the hyperpolarization-activated current. Int J Mol Sci 927 **16**:3071–3094. doi:10.3390/ijms16023071
- 928 Wainger BJ, DeGennaro M, Santoro B, Siegelbaum SA, Tibbs GR. 2001. Molecular mechanism 929 of cAMP modulation of HCN pacemaker channels. *Nature* **411**:805–810.
- 930 doi:10.1038/35081088
- 931 Wang Z-J, Blanco I, Hayoz S, Brelidze TI. 2020. The HCN domain is required for HCN channel 932 cell-surface expression and couples voltage- and cAMP-dependent gating mechanisms. J 933 Biol Chem 295:8164-8173. doi:10.1074/jbc.RA120.013281
- 934 Winum P-F, Cayla G, Rubini M, Beck L, Messner-Pellenc P. 2009. A case of cardiomyopathy 935 induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin 936 Electrophysiol PACE 32:942-944. doi:10.1111/j.1540-8159.2009.02414.x
- Yu H, Gall B, Newman M, Hathaway Q, Brundage K, Ammer A, Mathers P, Siderovski D, Hull 937
- 938 RW. 2021. Contribution of HCN1 variant to sinus bradycardia: A case report. J Arrhythmia
- 939 37:1337-1347. doi:10.1002/joa3.12598

**Table 1.** Clinical characteristics of the family members studied.

		Age at diagnosis	Heart Rate		e (bpm) Function Class (N		Functional Class (NYHA)		LVEF (%)		Treatment	
Patient	Gender	(year	Symptoms	Baseline	Α. Τ.	Deseline	A T	Deseline	A T	Ivabradine	Bisoprolol	
		range)		Mean 24 h	Mean 24 h	Baseline	A. I.	Baseline	A. I.	(mg BID)	(5 mg BID)	
					Carrie	rs						
II-1	М	61-65	Yes	95[13]		ш	ш	23				
III-1	М	36-40	No	100[15]	90[4]*	I	I	45	55	5	+	
III-3 (#)	F	31-35	Yes	106[17]	78[5]*		I	43	55	5	+	
III-7	F	26-30	Yes	101[13]	85[8]*	1-11	I	45	56	5	+	
IV-1	F	21-25	No	103[10]	82[19]*	I	I	51	57	7.5		
IV-4	М	11-15	Yes	111[12]	94[12]*	I	I	60	60	7.5		
IV-5	М	6-10	No	122[15]	101[10]*	I	I	64	64	5		
IV-8	F	11-15	No	112[14]	103[14]*	I	I	60	59	7.5		
IV-9	F	6-10	Yes	117[12]	102[12]*	I	I	63	64	7.5		
					Non car	riers						
II-5	М	56-60		80[15]				55				
III-5	М	41-45		79[13]				56				
III-8	М	41-45		46[14]				56				
111-9	М	41-45		79[11]				55				
IV-2	F	11-15		84[15]				59				
IV-3	М	16-20		75[15]				58				

#: Proband. A.T. : 3 months after initiation of treatment. BID: twice daily. F: female. HR: heart rate. LVEF: left ventricular ejection fraction. M: male. NYHA: New York Heart Association. Mean 24 h HR data are presented as mean[SD]. Student's t-test followed by Pearson correlation tests. \*P<0.05 vs baseline.

Tables-source data 1.

Patient	ECG parameters							Chamber characterisation								
	Resting Heart Rate (bpm)		P (ms	5)	PQ (m	ıs)	QRS (n	ns)	QT (m	ns)	QTc (n	ns)	LVEDD (	mm)	LVESD (I	mm)
	Baseline	A.T.	Baseline	Α. Τ.	Baseline	Α.Τ.	Baseline	Α.Τ.	Baseline	Α.Τ.	Baseline	Α.Τ.	Baseline	Α.Τ.	Baseline	A. T.
							CARRI	ERS								
II-1	117	-	100	-	120	-	96	-	310	-	380	-	53	-	44	-
III-1	106	73	110	120	140	150	90	90	320	360	390	400	55	56	43	39
III-3 (#)	107	77	120	120	200	160	80	90	320	360	390	400	53	52	40	40
III-7	108	83	100	100	160	160	80	100	320	340	390	400	50	53	33	40
IV-1	102	73	100	100	160	160	80	80	340	360	400	400	46	44	36	31
IV-4	119	90	80	100	180	200	80	80	310	340	390	410	49	50	33	34
IV-5	123	100	80	80	140	160	80	90	300	340	380	400	41	40	27	25
IV-8	123	87	80	100	120	140	80	80	300	340	380	420	45	46	31	30
IV-9	114	94	120	120	160	166	90	100	320	340	400	420	41	42	26	27
							NON CAF	RRIERS								
II-5	61	-	100	-	140	-	90	-	380	-	380	-	48	-	34	-
III-5	75	-	100	-	180	-	80	-	340	-	380	-	50	-	34	-
III-8	81	-	100	-	160	-	90	-	360	-	400	-	52	-	40	-
III-9	80	-	80	-	140	-	80	-	340	-	410	-	50	-	34	-
IV-2	82	-	80	-	120	-	80	-	360	-	410	-	43	-	30	-
IV-3	53	-	100	-	160	-	90	-	400	-	420	-	50,2	-	34,8	-

## **Table 2.** Resting ECG and cardiac structural parameters of all the family members studied.

A.T.: 3 months after treatment. bpm: beats per minute. ECG: electrocardiogram. F: female. HR: heart rate. LVEDD: left ventricular end-diastolic diameter. LVEF: left ventricular ejection fraction. LVESD: left ventricular end-systolic diameter. QT values were corrected using the Bazzet's and Fredericia's formulas in subjects with HR <100 and ≥100 bpm, respectively. Statistical comparison between baseline measurements and data after treatment was analyzed by paired Student t-tests. **Tables**-source data 1.

Gene	Genotype	Ancestral allele /Variant	dbSNP_ID	MAF	Aminoacid substitution	Transcript	Provean prediction	SIFT Prediction	Polyphen- 2 Prediction	Mutation Taster	CADD Score
CXADR	HET	C/G	-	-	L227V	NM_001338.5	Neutral	Tolerated	Benign	Disease causing	13.8
HCN4	HET	G/A	rs1207487211	0.000003982	V240M	NM_005477.3	Neutral	Deleterious	Probably damaging	Disease causing	28.9
LDB3	HET	-	-	-	P441_S448del	NM_007078.2	-	-	-	-	-

**Table 3**. Summary of all nonsynonymous variants identified in the proband.

CADD= Combined Annotation Dependent Depletion (A score greater of equal 20 indicates that it is predicted to be the 1% most deleterious substitutions that you can do to the human genome); HET= heterozygous; MAF= mean minor allele frequency from all ethnic groups where the variant has been identified as provided in https://gnomad.broadinstitute.org/; SIFT= Sorting Intolerant From Tolerant.

Table 4. Effects of p	0.V240M variant on the ti	ne- and voltage-depe	endent properties of	macroscopic and unita	ry HCN4 currents
-----------------------	---------------------------	----------------------	----------------------	-----------------------	------------------

			Whole-ce	II			
HCN4	E <sub>rev</sub> (mV)	Vh <sub>act</sub> (mV)	Kact	ΔI <sub>NS</sub> /I <sub>SS</sub>	τ <sub>deact</sub> (s)	I <sub>HCN4</sub> density -160 mV (pA/pF)	l <sub>HCN4</sub> density -60 mV (pA/pF)
WT	-6.0±1.9	-131.3±2.5	11.5±0.7	0.62±0.07	0.9±0.2	-43.1±4.7	-1.2±0.2
p.V240M	-6.8±2.3	-111.7±2.6*	12.3±0.7	0.79±0.03*	2.1±0.4*	-128.5±21.2*	-8.6±2.6*
WT+p.V240M	-6.5±1.6	-120.1±2.7*#	13.0±1.0	0.68±0.06	1.4±0.2	-72.9±8.3*#	4.3±1.5*#
			Single-chan	nel			
HCN4	τ <sub>ΟΡΕΝ</sub> (ms)§	τ <sub>closed</sub> (ms)§	MOT (ms)	<i>f</i> ₀ (Hz)	Po	<i>і</i> <sub>нс№4</sub> –90 mV (рА)	γ (pS)
WT	17.3	68.1	36.2±9.8	5.2±1.1	0.11±0.02	-1.6±0.3	16.3±2.7
p.V240M	9.3*	18.6*	17.1±3.5*	13.2±1.0*	0.23±0.03*	-2.9±0.4*	39.8±4.2*

 $\Delta I_{NS}/I_{SS}$ = ratio between the instantaneous current ( $I_{INS}$ ) and the steady-state current ( $I_{SS}$ ) generated by the pulse protocol used to determine the deactivation kinetics after 1-s interval at -40 mV between the two test pulses to -120 mV. MOT= mean open time. P<sub>o</sub>= open probability.  $\tau_{OPEN}$  = open time constant yielded by the fit of a monoexponential function to the open time histogram.  $\tau_{CLOSED}$  = closed time constant yielded by the fit of a monoexponential function to the closed time histogram. Each value represents mean±SEM of >5 cells/experiments (biological replicates) from at least 3 different dishes in each group. Statistical comparisons were made by using ANOVA followed by Tukey's test (Whole-cell) or using *t*-test (single-channel). \*P<0.05 vs WT; #P<0.05 vs p.V240M. §These values are obtained by the fit of a monoexponential fit to the curves constructed with the respective mean values

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

Table 5. Characteristics of the AP generated by a mathematical model of the human sinoatrial node action potential

Parameter	wт	p.V240M	WT+p.V240M
Cycle Length (ms)	814	410	555
Frequency (Hz/bpm)	1.23/73.8	2.44/146.3	1.80/108.1
Diastolic depolarization rate (mV/s)	48.1	126.7	76.7
Mean Diastolic Potential (mV)	-58.9	-57.5	-58
Action potential amplitude (mV)	85.3	81.5	84.0
Overshoot (mV)	26.4	24.0	26.0
APD <sub>20</sub> (ms)	98.5	85.0	93.2
APD <sub>50</sub> (ms)	136	122.9	129.6
APD <sub>90</sub> (ms)	161.5	148.7	155.0

 $APD_{20}$ ,  $APD_{50}$ ,  $APD_{90}$ = action potential duration measured at 20%, 50% and 90% of repolarization; bpm= beats per minute.